We have just launched our AI-enabled Route Scouting Service, which aims to streamline synthetic route identification for novel APIs by combining our global chemical supply chain intelligence and in-house expertise with AI technology from Elsevier. bit.ly/3xXcMsK

Today we reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with our business performance well on track to deliver our Full-Year Outlook. Read more: bit.ly/3WAPZNa

We have just added clinical bottling and labeling capabilities at our Small Molecules site in Bend, Oregon (US), enabling us to speed up product delivery to clinical trial centers, which is crucial in its customers' journey toward clinical trials. bit.ly/3WTrN8Q

Very honored to attend ⁦⁦Lonza⁩ Safety & Wellness Day! Hugely impressed by Lonza‘s commitment to safety and wellbeing of its over 1000 employees in 🇸🇬! A great example of a🇨🇭company contributing to the lion city! Thanks also to ⁦⁦Singapore Civil Defence Force for their presence!

We have just completed an expansion of our mid-scale microbial manufacturing facility in Visp, Switzerland. The new facility enhances our microbial manufacturing scale flexibility and will allow us to meet a broad range of drug developers' needs. bit.ly/4geQuo8

Today, we inaugurated our newest facility - the Innovaform Accelerator, to serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration. bit.ly/4e5XAd5

We have just signed a long-term commercial supply agreement for CASGEVY® with Vertex Pharmaceuticals. We will manufacture CASGEVY® at our cGMP cell therapy manufacturing facilities in Geleen (NL), with plans to expand to our Portsmouth (US) facility. bit.ly/47BJugW

Today, we completed our acquisition of the Genentech biologics manufacturing site in Vacaville, California from Roche for USD 1.2 billion. The Vacaville facility significantly extends our mammalian manufacturing footprint in the US, the world’s largest pharmaceutical market.

In our Q3 qualitative update, we reported performance is on track to deliver on our Full-Year Outlook, with a strong Q3 commercial and operational performance across the CDMO business. bit.ly/3YAvH7x

We have just completed the first GMP product batch supported from our recently completed next-generation mammalian manufacturing facility in Portsmouth (US). bit.ly/4hUo7fL

We have just expanded our service offering for orally delivered biologic therapies to support the unique development and manufacturing needs of smart capsules companies. bit.ly/3OB26F9

Looking for your next opportunity? We’ve just launched our brand new careers site, designed to make finding and applying for your next role easier than ever. Visit Lonza.com/careers to see how you could make an impact with us.

Today, we reported our financial results for Full-Year 2024, with sales of CHF 6.6 billion. A CORE EDITDA of CHF 1.9 billion resulted in a robust margin of 29.0%, driven by high demand for commercial CDMO services and strong operational execution. lonza.com/news/2025-01-2…

Today we launch our simplified and streamlined operating model. Based on our “One Lonza” vision and strategy, this transformation unites our core competencies to fulfil our vision to be a pioneer and world leader in the CDMO industry. bit.ly/3YdvlDf

Today we published our Annual Report 2024 and Sustainability Report 2024, giving a comprehensive overview of our progress towards our long-term business and sustainability goals. bit.ly/4iXTqGA

In our Q1 qualitative update, Lonza reported a strong performance in line with expectations for Full-Year 2025, driven by robust commercial demand in our CDMO business and high utilization in the early-stage business. bit.ly/433nOZh

We have just launched our Design2Optimize™ platform, to enhance the process development and manufacturing of small molecule APIs. bit.ly/43xuorp

📢 We are delighted to announce that Lonza's Chief #Legal & Corporate Affairs Officer Andreas Bohrer has joined as a Member of our Executive Board to help advocate our mission at the OECD ➡️ Better Policies for Better Lives. Nominated by our member economiesuisse, Andreas brings a wealth of experience in

We have seen a strong financial performance in H1 2025, with CHF 3.6 billion sales resulting in 19.0% CER sales growth, and a CORE EBITDA of CHF 1.1 billion resulting in a robust margin of 29.6%. Read more about our progress in H1 2025 here: bit.ly/4lSTbxO

Today, we announced a collaboration with RION to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond. Read more: lonza.com/media-advisori…